Ocean Biomedical provides latest updates on its broad programs

Ocean Biomedical shared an update on its broad range of promising programs in malaria, fibrosis, and multiple cancers. On September 14, 2023, Ocean Biomedical will host a Research and Development Day, featuring a live Q&A with its Scientific Co-founders. The research, breakthrough discoveries, and current undertakings of each of Ocean Biomedical’s cancer, malaria, and pulmonary fibrosis programs are discussed in more detail below. Cancer Program. Updates on Ocean’s late-stage preclinical work in oncology include: Recent results showing the effectiveness of anti-CHi3L1 in brain cancer, creating a 60% reduction in tumor growth in human glioblastoma multiforme stem cell model in vivo; Recent results showing major lung cancer tumor reduction of 85%-95% in primary lung cancer models of non-small cell lung cancer; Experimental results demonstrating Ocean’s antibodies inhibit pulmonary metastasis, including malignant melanoma; and Extension of patent protections in the U.S. and overseas to cover potential treatments for multiple cancers, including breast cancer, prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, lung cancer, brain cancer, and skin cancer. Malaria Program. Recent updates include: Advancing understanding and control of the mechanisms by which Ocean’s PfGARP antigen induces malaria parasite death; Optimizing and developing an mRNA vaccine candidate based on discoveries of PfGARP, PfSEA, and another antigen that may be able to simultaneously target the malaria parasite at different stages of the blood cycle, ideally for prevention in sub-Saharan Africa; Advancing a new therapeutic candidate for treating severe malaria; and Advancing a new therapeutic candidate for malaria prevention, ideally for use by tourists, business travelers, or in short-term deployment situations. Fibrosis Program. Progress includes: Testing Ocean’s anti-fibrotic treatment candidate, “OCF-203,” which has generated impressive reductions of fibrosis in multiple models and reduced collagen accumulation by 85%-90%; Experimenting with ‘pale ear’ mouse models, which have shown potential as a treatment candidate for Hermansky-Pudlak Syndrome, a rare disease that may hold potential for orphan drug designation; and Evaluating Ocean’s anti-fibrotic treatment candidates’ potential for use beyond IPF and HPS, with possible application in scleroderma, alcoholic liver disease, and non-alcoholic steatohepatitis.